Menu
Search
|

Menu

Close
X

AMAG Pharmaceuticals Inc AMAG.OQ (NASDAQ Stock Exchange Global Select Market)

11.79 USD
-0.50 (-4.07%)
As of Sep 13
Previous Close 12.29
Open 12.35
Volume 316,799
3m Avg Volume 343,956
Today’s High 12.38
Today’s Low 11.76
52 Week High 23.77
52 Week Low 6.81
Shares Outstanding (mil) 35.29
Market Capitalization (mil) 661.66
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.78 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY19
154
FY18
474
FY17
496
FY16
532
EPS (USD)
FY19
-7.116
FY18
-4.920
FY17
-6.328
FY16
-0.158
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
1.12
7.91
Price to Book (MRQ)
vs sector
0.70
5.38
Price to Cash Flow (TTM)
vs sector
9.04
24.36
Total Debt to Equity (MRQ)
vs sector
81.25
14.55
LT Debt to Equity (MRQ)
vs sector
81.25
10.20
Return on Investment (TTM)
vs sector
-2.17
14.48
Return on Equity (TTM)
vs sector
-4.83
15.78

EXECUTIVE LEADERSHIP

Gino Santini
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
William Heiden
President, Chief Executive Officer, Director, Since 2017
Salary: $780,635.00
Bonus: $879,600.00
Edward Myles
Chief Financial Officer, Executive Vice President, Treasurer, Since 2017
Salary: $456,794.00
Bonus: $323,700.00
Elizabeth Bolgiano
Chief Human Resource Officer, Executive Vice President, Since 2017
Salary: --
Bonus: --
Joseph Vittiglio
Executive Vice President, General Counsel and Corporate Secretary., Since 2017
Salary: $401,670.00
Bonus: $167,400.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1100 Winter St
WALTHAM   MA   02451-1427

Phone: +1617.4983300

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

SPONSORED STORIES